A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 主要假设： ART中断前接受MRK Ad 5疫苗的受试者中ART中断后第12周和第16周的HIV-1 RNA几何平均水平低于接受安慰剂的受试者。 在ART中断后16周步骤中，接受MRK Ad 5疫苗的受试者中Log 10 HIV-1 RNA拷贝/mL与日函数的时间平均曲线下面积低于接受安慰剂的受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Hypothesis: The week 12 and week 16 post-ART interruption geometric mean HIV-1 RNA levels will be lower among subjects who had received MRK Ad5 vaccine prior to ART interruption than among subjects who received placebo. The time average area under the curve of the Log10 HIV-1 RNA copies/mL versus day function in the 16 week post-ART interruption step will be lower among subjects who receive the MRK Ad5 vaccine prior to ART interruption than among subjects who receive placebo.